01144nas a2200373   4500000000100000000000100001000000100002008004100003653003100044653002800075653005600103653002600159653003000185653001100215653001600226653004300242653003700285653005800322653002300380653001400403653003200417653002700449653002700476653001400503653002400517100001400541700002000555700001300575245013400588250001500722300001200737490000700749020001400756       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones10aAdrenergic beta-2 Receptor Agonists/therapeutic use10aBronchodilator Agents10aDrug Therapy, Combination10aHumans10aMiddle Aged10aMuscarinic Antagonists/therapeutic use10a*Pneumonia/epidemiology/etiology10a*Pulmonary Disease, Chronic Obstructive/complications10aCOPD exacerbations10aDatabases10along-acting bronchodilators10anew user cohort design10aobservational research10apneumonia10areal-world evidence1 aS. Suissa1 aS. Dell'Aniello1 aP. Ernst00aDiscontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice  a2022/04/09  a133-1410 v19  a1541-2563